Authors:
Brad Millson¹, Sherri Thiele¹, Yvonne Zhang¹, Wendy Dobson-Belaire¹, Brett Skinner²

Author Affiliations:
¹IMS Health Canada Inc., 16720 Trans-Canada Highway, Kirkland, Quebec H9H 5M3
²Innovative Medicines Canada, 55 Metcalfe Street, Suite 1220, Ottawa, Ontario K1P 6L5

Foreword provided by:
Russell Williams, President, Innovative Medicines Canada
# Table of Contents

Forward ................................................................. 1  
Summary ................................................................. 2  
Highlights ................................................................. 5  
1.0 About the Report ..................................................... 7  
2.0 Health Systems: Structure and Design ......................... 13  
3.0 Results: Comparing Access To New Medicines In Public Drug Plans .............................................. 16  
4.0 Conclusion ............................................................. 23  
5.0 Appendix ............................................................... 24  
6.0 About Innovative Medicines Canada .......................... 32
To the reader,

Innovative Medicines Canada is pleased to publish the 2016 edition of our annual report comparing coverage for new medicines under public drug plans in Canada and other countries. Since 2006, Innovative Medicines Canada has been examining access to new medicines in a global context in order to gauge the performance of Canada’s healthcare system. The findings of this report provide important information that has practical implications for the health of Canadians.

According to the World Health Organization (WHO), access to medicines and vaccines is a key component to a quality health system. There is no doubt that innovation in medicines and vaccines has made a significant contribution to improving health outcomes in Canada and around the world. It is therefore important for Canadians to know the state of access to new medicines in their country, relative to comparable countries. The goal of this study is to measure access against international benchmarks in order to drive improvements to access here at home.

Innovative Medicines Canada is committed to engaging in policy issues from an evidence-based perspective. Our industry is also an important part of Canada’s life sciences sector, and our companies play a critical role in the Canadian economy.

Our member companies support 31,000 high quality jobs, contribute 3.8 billion dollars to our economy, and invest over one billion dollars in research and development each year.

Today, we have in hand the tools we need to manage and often cure diseases. With personalized medicine, we are further targeting therapies to patients’ genetic makeup and minimizing side effects. People are living full, productive lives where for many, that wasn’t an option even just a few years ago.

Globally, there are over 7,000 new medicines in development. There are 1,800 oncology medicines in development. Five hundred in mental health, and nearly 1,400 in neurological disorders. Over 1,200 medicines are in development to fight infectious diseases, 600 to manage cardiovascular disorders, 475 for diabetes and 1,120 for immune disorders.

Fair and equitable access to innovative medicines across the country means that Canadians can benefit from a world-class healthcare system where cutting-edge treatments can turn chronic, debilitating and sometimes life-threatening illnesses into a thing of the past.

Russell Williams
President
Innovative medicines make an important contribution to achieving good health. It is therefore important that Canadians are well-informed about the state of access to new medicines in Canada. For this reason, Innovative Medicines Canada annually examines how well Canada’s public drug plans are performing on access to new medicines compared to public drug plans in other countries.¹

In 2014 Innovative Medicines Canada partnered with IMS Health to develop a sophisticated and transparent methodology using data compiled by IMS Health which was published as part of the 2015 Annual Report. The study examined access to new medicines in the context of the health care systems across a group of countries that are most comparable to Canada in terms of economic development. Specifically, the report compared coverage for new medicines under public drug plans in the wealthiest Organization for Economic Co-operation and Development (OECD) countries (for which complete data were available) according to the drug approvals, commercial launch rates, public reimbursement rates, scope of reimbursement and wait times for reimbursement in each country. In total 18 countries were included. Based on feedback and discussions following the release of the 2015 Annual Report, Innovative Medicines Canada decided to continue this partnership with IMS Health to provide an updated study including a total of 20 OECD countries and a refined methodology.

This study compares public drug plan coverage against the particular basket of new medicines approved for sale within each country. All new molecular entities (NMEs) or combinations containing at least one new NME granted national marketing authorization by each country’s national regulator during the five year period between January 1, 2010 and December 31, 2014 were included. NMEs or

¹ Data are not currently available to allow for an international comparison of access that would include private sector drug plans.
NME-containing combinations were considered new if they had not been previously approved or available in that specific country. The new medicines were selected for each country using the applicable, publicly available health regulatory agency approval lists. For example, in Canada, medicines with marketing authorization were identified from the Health Canada Notice of Compliance (NOC) database. In Europe, this list was determined from the pan-country European Medicines Agency (EMA) database with a subsequent launch status investigation to ensure molecules were NMEs on an EMA country by country basis. While some products in Europe could be granted market authorization directly from a country’s own health authority instead of the EMA, they were not included given the infrequent nature of these occurrences.

Reimbursement status was current as of December 2015, allowing for one full year to mature following the end of the five-year marketing authorization period that sets the parameters for the drugs included in this study. In general, most countries make public drug plan reimbursement decisions at the national level. Canada and the US are outliers in that reimbursement decisions are made separately and independently at the federal, provincial, or state level, creating a challenge in assigning a nationally representative measure of access to new medicines. As such, a unique approach was developed for the original study for both Canada and the US that weighted the observed drug reimbursement findings in each plan by taking into account the proportion of the population that was eligible for coverage under the public drug plan and aggregating across the country as a whole. In the US, public reimbursement was determined based on Medicare Part B and Part D. Under the US Medicare model private insurers provide drug coverage within a publicly funded scheme to eligible populations. For this report, coverage for new medicines was measured across the six largest private insurers that combined cover 83% of Medicare lives. For both Canada and the US, reimbursement was measured at three levels: 1) the product was listed in at least one of the Canadian provinces or US plans examined, 2) the product was available for 50% of the eligible national public drug plan population covered in each respective country, and 3) the product was available for 80% of the eligible national public drug plan population covered in each respective country.
The study examined access to new medicines in the context of the health care systems across a group of countries that are most comparable to Canada in terms of economic development.

Notable changes from the first report include:

- We have advanced the study period defining the basket of drugs to the most recent 5-yr marketing authorization period from January 1, 2010 to December 31, 2014.

- The removal of fixed dose combination (FDC) products composed only of molecules previously launched within a country. FDC products not containing NME molecules can often have quicker reimbursement if the composite molecules are already reimbursed which could skew an analysis that intends to focus on new medicines.

- Improved data availability permitted the country comparison list to be expanded to include South Korea, Portugal and Spain. Denmark was removed from the list of OECD countries included due to the difficulty in standardizing reimbursement information year over year.

- Reimbursement coverage time period consideration advancement from June 2014 to end of 2015.

- The removal of First-In-Class and World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) sub-analyses since these analyses were difficult to compare across countries in a meaningful way.

The findings from this report represent the most current and robust assessment currently available about how governments support access to new medicines in Canada in comparison with a group of Canada’s economic peer countries, and builds on other global research on the subject of access to medicines.²

OVERALL

• When only considering products that were reimbursable across provinces accounting for at least 80% of the eligible national public drug plan population, Canada ranked 18th of 20 countries with only 37% of new medicines receiving public reimbursement across the country.

• In Canada, the wait from national marketing approval to public drug plan reimbursement was 449 days across provinces comprising 80% of the eligible national public drug plan population, ranking Canada 15th of 20 countries.

• Canadian public drug plans placed reimbursement conditions on 90% of new medicines when measured across provinces comprising 80% of the eligible national public drug plan population, ranking Canada 17th of 20 countries.

BIOLOGICS

• In Canada, 23% of new biologic medicines were reimbursed in public drug plans across provinces comprising at least 80% of the eligible national public drug plan population, ranking Canada 19th of 20 countries.

CANCER

• In Canada, 59% of cancer medicines were covered in public drug plans across provinces comprising at least 80% of the eligible national public drug plan population, ranking Canada 17th of 20 countries.
In Canada, the wait from national marketing approval to public drug plan reimbursement was 449 days across provinces comprising 80% of the eligible national public drug plan population, ranking Canada 15th of 20 countries.

**CONSOLIDATED RESULTS**

- The relative international performance of Canada’s public drug plans is illustrated below. Countries that fall into the upper left hand quadrant showed higher rates of public reimbursements for new medicines and shorter time to public reimbursement. Countries in the bottom right quadrant showed lower rates of reimbursement, and longer time to reimbursement. Relative to the average bubble size, countries with a smaller/larger bubble size had more/less restricted reimbursement than the average across countries.

1. Listed in one province/Medicare plan;
2. Covered for 50% of the eligible public drug plan population;
3. Covered for 80% of the eligible public drug plan population

Bubble size pertains to the percent of new medicines reimbursed without restrictions (i.e. fully reimbursed), indexed to the average across countries.
1.0 ABOUT THE REPORT

This report is the latest evolution of the work by Innovative Medicines Canada to objectively compare access to new medicines across the public drug plans of Canada and its peer countries. The report builds on previous editions, broadening the global perspective, and refining the methodology to support study stability and ensure countries are compared fairly and evenly in the context of highly unique health care systems. The analysis begins with a review of the process, mechanisms, and scope of public drug plan reimbursement across countries. From there, several key analyses were conducted to compare access to new medicines in publicly funded drug plans, including:

- **New Medicines**: Identifying the new medicines approved for sale in each country between January 1, 2010 and December 31, 2014.
- **Proportion Launched**: The proportion of newly approved medicines that were subsequently made available and sold up to December 31, 2015.
- **Proportion Reimbursed**: The proportion of newly approved medicines that were reimbursed under public drug plans as of December 31, 2015.
- **Restrictions and Criteria**: Comparing the quality of reimbursement by looking at product-specific prescribing restrictions and criteria for use imposed on reimbursed products.
- **Time to Launch and Time to Reimbursement**: Calculating the time elapsed from marketing approval to launch and from approval to reimbursement across countries.
- **Sub-Analyses**: Determining if differences in access exist in sub-segments of interest such as cancer and biologics.
1.1 COUNTRIES OF FOCUS

The study focused on 20 of the top 30 OECD countries ranked by highest GDP per capita, as listed below (Table 1). This subset of OECD countries was selected because the countries are most similar to Canada in terms of social and economic factors and comparable and complete data was available to measure reimbursement for new medicines within their public drug plans.

Table 1: OECD countries analyzed

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>CA</td>
<td>Ireland</td>
<td>IE</td>
<td>South Korea</td>
<td>KO</td>
</tr>
<tr>
<td>Australia</td>
<td>AU</td>
<td>Italy</td>
<td>IT</td>
<td>Spain</td>
<td>ES</td>
</tr>
<tr>
<td>Austria</td>
<td>AT</td>
<td>Japan</td>
<td>JP</td>
<td>Sweden</td>
<td>SE</td>
</tr>
<tr>
<td>Belgium</td>
<td>BE</td>
<td>Netherlands</td>
<td>NL</td>
<td>Switzerland</td>
<td>CH</td>
</tr>
<tr>
<td>Finland</td>
<td>FI</td>
<td>New Zealand</td>
<td>NZ</td>
<td>United Kingdom</td>
<td>UK</td>
</tr>
<tr>
<td>France</td>
<td>FR</td>
<td>Norway</td>
<td>NO</td>
<td>United States</td>
<td>US</td>
</tr>
<tr>
<td>Germany</td>
<td>DE</td>
<td>Portugal</td>
<td>PO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1.2 DATA SOURCES

IMS Health propriety databases, including MIDAS™ and Pricing Insights™, were used as the primary source of product and country specific data regarding product launch and reimbursement. These actively managed datasets bring together health care facts and figures from over 70 countries, allowing for multi-country analyses in a systematic and uniform approach. Data was also collected from public sources, including national health regulatory agencies, and non-governmental organizations. More details on the data sources are provided in the Appendix of this report. Additionally, this report drew on input from IMS Health subject matter experts across the world to review the data and methodology, as well as provide additional insights and context to the findings.

Reimbursement status continuously evolves. Data used in this report is current to December 2015.

1.3 PRODUCT SELECTION

Throughout the report, all new molecular entities and new combinations selected for analysis will be referred to as “new medicines”. All new molecular entities or new combinations granted national marketing authorization between January 1, 2010 and December 31, 2014 were included in the analysis. New medicines or new medicine-containing combinations were considered new if they had not been previously approved or available in that specific country. Unique product lists were generated for each country. For details regarding exclusion criteria, see Appendix 5.2.1.

The new medicines were selected for each country using the applicable, publicly available health regulatory agency approval lists. In Europe, this list was determined from the pan-country EMA.

---


For Canada, the reimbursement decision is made independently by each province, and as such, the same product reimbursed in one province may not be reimbursed in another, adding to the complexity of a global comparison. In order to fully understand the reimbursement levels for Canada, this analysis uses three benchmarks:

1. **Products with at least one public drug plan approval**: Tracks all products that were listed for coverage in at least one provincial drug plan.

2. **Products reimbursed for 50% of the eligible national public drug plan population**: Tracks all products that were covered for at least 50% of the total national population that was eligible for publicly funded drug plan benefits, and was calculated using a weighted average by province.

3. **Products reimbursed for 80% of the eligible national public drug plan population**: Tracks all products that were covered for at least 80% of the total national population that was eligible for publicly funded drug plan benefits, and was calculated using a weighted average by province. This level of reimbursement represents coverage for most Canadians, and in the context of this global analysis, best represents the reimbursement coverage in comparator OECD countries.

**1.4 LAUNCH AND PUBLIC REIMBURSEMENT ANALYSIS**

A new product was considered “launched” if it had been introduced into the market. The date of market introduction was considered the “launch date”. Launch status and date of launch were identified for each of the selected products by country using the IMS Health MIDAS™ database.

Reimbursement measured whether or not the new product was granted public reimbursement, and/or included in a government-mandated reimbursed medicines list. The corresponding date on which the reimbursement was granted was defined as the “reimbursement date”. Reimbursement status was determined using information from the IMS Health Pricing Insights™ database, as of December 31, 2015. Reimbursement status was also supplemented with local country reimbursement sources where necessary and/or applicable. This analysis only tracks the status of medicines on public reimbursement systems.

---

Eligibility for public reimbursement can vary by country, with most countries in Europe providing coverage to the entire population, while countries like Canada and the US mainly provide coverage to select populations. This study focuses only on public coverage of medicines as a proportion of the population eligible under public plans, notwithstanding supplementary private drug coverage or cash paying customers.

In general, most countries make public reimbursement decisions at the national level. Canada and the US are outliers in that the individual provinces, states and/or plan administrators make independent regional reimbursement decisions, creating a challenge in understanding national access to medicines. As such, as part of the a unique approach was developed for both Canada and the US, taking into account the proportion of the eligible national public drug plan population that was granted access to each new medicine.

In the US, public reimbursement was determined based on Medicare Part B and Part D. Coverage was determined across the six largest private insurers that combined, cover 83% of Medicare lives. Similar to Canada, product reimbursement was determined at 3 levels: 1) the product was listed in at least one of the four aforementioned plans, 2) the product was available for 50% of the population covered under any of the four plans considered, and 3) the product was available for 80% of the population covered under any of the four plans considered. Additional details can be found in the appendix of this report.

It is important to note that some countries have special access programs for exceptional circumstances that are not part of an official formulary. These special access programs were not included in the analysis as they are not widely available, are typically on an individual case-by-case basis, and have limited public transparency for empirical evaluation.

1.5 SUB-ANALYSES

Additional analyses were conducted to understand if there were any differences in how countries provide access to specific types of products.

**Biologics**: This group was selected as they are typically high cost, yet innovative, medicines. All products that were produced from biological sources or systems were included, such as antibodies, hormones, and enzymes.

**Cancer**: Many nations put a priority on life-threatening diseases, such as cancer. Cancer products were identified using the WHO ATC class L classification and eliminating non-oncologic immunomodulating agents. The final list was validated by IMS Health expertise.
1.6 QUALITY OF REIMBURSEMENT

Moving beyond a binary analysis of reimbursement, this metric provides insight into how broadly reimbursed products are made available to the eligible national public drug plan population, and how extensively countries impose restrictions on access. This analysis disregards any system-wide eligibility restrictions or co-pays, and instead focuses on restrictions uniquely assigned to individual products. Each product was categorized into one of three levels in increasing order of restriction:

1. **Full reimbursement**: The new product received the highest level of reimbursement available for that country.

2. **Partial reimbursement**: Only part of the product’s eligible cost is covered.

3. **Restricted reimbursement**: Access to the reimbursed product was restricted to a subset of the eligible national public drug plan population, or required special authorization or prerequisite conditions to be met.

Products with more than one level of coverage were categorized according to their most restrictive condition. Partial reimbursement was not applicable in Canada as no province employs variable co-pays at the product specific level.

1.7 TIME TO LAUNCH AND TIME TO REIMBURSEMENT

In addition to measuring the extent of reimbursement across countries, it is also important to examine the speed at which new medicines are made available. These metrics look at the time required to access new medicines, starting from the date of health regulatory approval in each country.

- **Time to launch**: The time, measured in calendar days, from the date of market authorization to the date of introduction on the market. This is an indicator of the relative time each company required to make their product generally available to the public.

- **Time to reimbursement**: The time, in days, from the date of market authorization to the date of public reimbursement. This is an indicator of the time required for public payers to review and include new medicines in their formularies.

The date of marketing authorization was available at the exact day, month, and year, whereas dates of launch and reimbursement were available only at month and year. As such, in order to calculate the time to launch and time to reimbursement in calendar days, the date of launch and reimbursement was set at the 15th of the month, to equally balance for all products launched or reimbursed before and after this date. Where the calculation yielded a negative value, the days to launch or reimbursement were set to zero.

- In Canada, the time to reimbursement was calculated as the average time from NOC (notice of compliance) to reimbursement for all products in each province. The average time to reimbursement for each province was then weighted by the relative size of the eligible national public drug plan population in each province to determine a final weighted average time to reimbursement.
1.8 NON-COMPARABILITY WITH PREVIOUS REPORTS

This report marks the second iteration of a partnership with Innovative Medicines Canada and IMS Health to comparatively assess the access to new medicines across comparable countries; however, study to study comparability is not valid for a number of reasons:

• The list of new medicines considered from study to study varied and is expected to vary year over year as novel new medicines are considered and aged medicines are removed. Thus we have advanced the study period defining the basket of drugs to the most recent 5-yr marketing authorization period from January 1, 2010 to December 31, 2014.

• The present study refined new medicine inclusion methodology to only consider FDC containing at least one new molecule to minimize reimbursement bias. FDC products not containing new molecules can often have quicker reimbursement if the composite molecules are already reimbursed.

• The present study expanded the list of countries compared to Canada include South Korea, Portugal and Spain to broaden the comparative findings amongst countries with reliable medicine authorization, launch and reimbursement information. Denmark was removed from the list of OECD countries included due to the difficulty in standardizing reimbursement information year over year.

• Reimbursement coverage time period consideration was advanced from June 2014 to end of 2015 to again keep findings current but also standardized all periods of consideration to end of calendar year.

• The study focused on biologic and cancer class sub-analyses.
2.0 HEALTH SYSTEMS: STRUCTURE AND DESIGN

Each country has its own political priorities, economic constraints, and cultural expectations when it comes to health care. These factors and others lead to significant diversity in how health care is administered and delivered. For this report the structure of each health system was analyzed to develop a contextual understanding of the drug coverage model in each country.

2.1 COMPONENTS OF A HEALTH SYSTEM

The World Health Organization (WHO) defines a health system as the sum of all organizations, institutions and resources whose overall objective is to improve health. These systems operate with the aim to improve people’s lives in everyday tangible ways, including a broad spectrum of activities from disease prevention to treatment and management.

A good health system is one that “delivers quality services to all people, when and where they need them”. The WHO has listed several key components of an effective health system: health system financing, health workforce, health information and resources, national health policies and essential medicines and health technologies.

- **Health systems financing** can range from general taxation to fee for service models. These financing methods ensure that funds and resources are allocated equally, are sustainable, and can reduce barriers to access to health care in a system where the goal is to achieve universal coverage.

- **A highly skilled and knowledgeable health workforce** is an essential component in providing quality care in complex medical settings.

---


• **Health information and resources** are the foundation for efficient and effective management of a health system by providing access to information. Health information allows for informed and appropriate health decision making, health sector reviews, planning, resource allocation and program monitoring and evaluation.

Structural differences between health care systems can impact how the burden of cost is distributed across governments, employers, and individuals, and thus may confuse comparisons of access to new medicines across public drug plans.

• **National health policies** set the strategic direction of a country and can directly highlight key priorities for a nation. Policies can also help to correct undesirable trends and regulate the behavior of actors in the health care field. Overall, national health policies help to establish transparency and accountability in the health system.

• **Access to affordable medicines, vaccines, and health technologies** are a key component to a quality health system. These represent the arsenal that medical professionals have as a means to combat diseases and treat illness.

### 2.2 HEALTH CARE SYSTEM FINANCING & REIMBURSEMENT POLICIES

Structural differences between health care systems can impact how the burden of cost is distributed across governments, employers, and individuals, and thus may confuse comparisons of access to new medicines across public drug plans. For example, many countries publicly fund prescription drug costs on a universal basis for their entire populations. With some variation between them, other countries such as the Netherlands, Switzerland and Germany utilize universal mandatory private health insurance supported by public subsidization for individuals. In the Netherlands and Switzerland health systems, basic health insurance is mandatory for all residents, who are free to choose from a set of private plan providers, and there is substantial public subsidization of the costs for individuals. The United States has a public system in place that covers seniors, low income households, and disabled persons (Medicare and Medicaid), with private drug plans covering the remaining population. Furthermore, in the US, this public coverage, while paid publicly, is administered by private insurance carriers. As of 2010, the US system also requires that all individuals must obtain a government-approved private health insurance policy that includes prescription medicines if the person is not already covered by an employer sponsored health plan, Medicaid, Medicare or other public insurance programs.
In Canada, each provincial and territorial government offers a drug benefit plan for eligible groups, as does the federal government for the eligible populations under its specific jurisdiction. Most provincial/territorial drug insurance systems are separate public-private sector models, others are income-eligibility and deductible-based universal public programs with supplemental private coverage (e.g. British Columbia, Saskatchewan), while others are closer to social insurance models (e.g. Quebec, New Brunswick). Most jurisdictions have specific programs for population groups that may require more enhanced coverage for high drug costs, including seniors, recipients of social assistance, and individuals with diseases or conditions that are associated with high drug costs.

For the purposes of facilitating comparisons in this report, the universal mandatory private health insurance systems and the social insurance health systems were deemed to have universal public drug plans, because the public element (subsidization) could not be treated separately from the private element given available data. For the US health system, Medicare was used as the comparative public drug plan for the purpose of this comparative analysis.

The process by which countries make public drug plan reimbursement decisions for new medicines is another critical element to understanding differences in international access to medicines. This approach typically starts with a marketing authorization body which approves the sale of new medicines, followed by a body that conducts a health technology assessment (HTA) and finally a body that makes reimbursement decisions. Generally, most nations have a centralized marketing authorization, HTA body and reimbursement process, and these groups are usually separate organizations. In Canada, medicines are approved for sale through the national regulatory agency (Health Canada). Subsequently, for public consideration of formulary listing in all provinces besides Quebec, new medicines undergo a national HTA through the Canadian Agency for Medicines and Technologies in Health (CADTH). Within Quebec, Institut national d’excellence en santé et services sociaux (INESSS) provides the analogous HTA function. Based on recommendations provided by CADTH national public medicine reimbursement list prices are privately negotiated by the pan-Canadian Pharmaceutical Alliance (pCPA). Provinces and federal drug plans then independently make the final decision on reimbursement for their covered population based on the confidential pCPA negotiated reimbursement price.

Co-payments may also be employed to manage public system affordability by shifting some of the cost-burden to the patient. Use of and scope for co-payments vary across countries and affects the comparability of drug coverage between drug plans. For example, Canada has income-based deductibles, co-payment systems, and out-of-pocket caps in place which vary by province.
3.1 MARKET AUTHORIZATION COMPARISON

The "basket" of NMEs that were approved for sale during the period of study varies by country. While there was significant overlap of new medicines across many countries, each country has a unique list of molecules which served as the basis for measuring access to new medicines in that country. Figure 1 compares the overlap of each country's basket of new medicines relative to Canada.

Figure 1: Overlap comparison of new medicines granted marketing authorization in Canada versus each comparison country.
3.2 LAUNCH AND REIMBURSEMENT COMPARISON

3.2.1 ALL NEW MEDICINES

The proportions of all new medicines launched and publicly reimbursed are shown in Figure 2. In Canada, 121 new medicines were granted marketing authorization between 2010 and 2014, out of which 108 (89%) were launched, ranking Canada 6th for proportion of new medicines launched. Of the 121 new medicines that were approved in Canada, 86 (71%) were publicly reimbursed in at least one province. At this level of reimbursement, Canada ranks 10th overall. However, at 50% eligible national public drug plan population coverage, the proportion of new medicines reimbursed dropped to 59% (ranking 16th), and at 80% eligible national public drug plan population coverage, only 37% of new medicines were reimbursed, putting Canada 18th out of 20 countries studied.

Figure 2: Percentage of new medicines launched and publicly reimbursed by country

1. Listed in one province/Medicare plan;
2. Covered for 50% of the eligible public drug plan population;
3. Covered for 80% of the eligible public drug plan population
3.2.2 BIOLOGIC MEDICINES

The proportions of biologics launched and publicly reimbursed are shown in Figure 3. In Canada, 65% of biologics were launched and 50% were reimbursed in one or more provinces, positioning Canada at 16th place. However, reviewing the coverage in at least 50% and 80% of the eligible national public drug plan population, reimbursement dropped to 38% (17th rank) and 23% (19th rank), respectively.

Figure 3: Percentage of new biologic medicines launched and publicly reimbursed by country

1. Listed in one province/Medicare plan;
2. Covered for 50% of the eligible public drug plan population;
3. Covered for 80% of the eligible public drug plan population

* Given the small variation among countries small annual differences can have a substantial impact on relative rank
3.2.3 CANCER MEDICINES

The proportions of cancer medicines launched and publicly reimbursed are shown in Figure 4. In Canada, 27 (22%) of all new medicines were cancer medicines, and 26 (96%) of these were launched. Of the 27 cancer medicines that were approved, 25 (93%) were reimbursed in at least one province. At this level of coverage Canada ranked 7th overall.

However, at 50% and 80% eligible national public drug plan population coverage, reimbursement rates dropped to 89% (ranked 9th) and 59% (ranked 17th) respectively. Given the broad public announcement of cancer therapy delisting from funding limitations of the UK Cancer Drugs Fund, relevant cancer medicine delisting were taken into consideration for the UK.

Figure 4: Percentage of new cancer medicines launched and publicly reimbursed by country

---

1. Listed in one province/Medicare plan,
2. Covered for 50% of the eligible public drug plan population,
3. Covered for 80% of the eligible public drug plan population

* Individual searching was carried out for cancer drugs in the UK given that there were a substantial number of reassessments that lead to delisting of 6 molecules in our list that were previously reimbursed

---

3.2.4 QUALITY OF REIMBURSEMENT

In order to understand and compare the extent to which countries impose reimbursement restrictions on new medicines, the quality of reimbursement was compared for each product by examining any product-specific prescribing or reimbursement restrictions imposed by the payer. The results are presented in Figure 5. For most countries, the results were compiled from national payer restrictions and criteria. In the US and Canada, in the absence of national payers, restrictions were examined at the carrier or provincial payer level, respectively. Results in the UK were taken from guidance issued by the National Institute for Health and Care Excellence (NICE). While not a national payer, NICE guidance is generally accepted and followed by local payers in England and Wales. Additionally, cancer products that were reviewed and granted access through the Cancer Drugs Fund were also captured in this analysis.

Canada was found to be among the most restrictive countries, with 91% of new medicines covered in at least one province having reimbursement criteria restricting broad access. This puts Canada 17th out of the 20 countries considered in this analysis. When considering only products with 50% and 80% eligible national public drug plan population coverage, the restrictions maintained a similar restriction level of 89% (17th rank) and 90% (17th rank), respectively, indicating that as products become more widely available across provinces, the likelihood of restrictions on their availability is similar.

The majority of restrictions captured for this analysis were at the national payer level. It should be noted that further access restrictions may also be imposed at the regional level which would be beyond the visibility of the study methods.
3.2.5 TIME TO LAUNCH AND REIMBURSEMENT

The last major metric we examined in our analysis was the time required to launch and reimburse new products by country. This measure gives an indication as to the extent to which patients are delayed access to new medicines by country. The results of this analysis are illustrated in Figure 6.

Time to reimbursement data were not available for the United States; however, CMS (Centers for Medicare and Medicaid Services) requires that, for products on Medicare part D, the P&T committee reviews a new FDA approved drug product within 90 days and will make a decision within 180 days of its release onto the market\(^1\). Therefore, the time frame of 180 days has been incorporated into the results. However, in the real-world setting, IMS Health expertise suggests that the time to reimbursement may fall closer to 90 days.

At 90 days, Canada was the second only to Japan as the quickest country to launch. However, the time needed to obtain public reimbursement was among the slowest, ranking 15\(^{th}\) of 20 countries overall. Time to listing (for ≥ 80% of the eligible national public drug plan population) was 449 days, 96 days longer than the average (353 days) and 104 days longer than the median (345 days) of all countries. There was no significant difference in the time to reimbursement between the three benchmarks of coverage (at least one province, 50% and 80% eligible national public drug plan population coverage), with 461 days, 453 days, and 449 days on average, respectively\(^2\).

Figure 6: Average time to launch and time to reimbursement from marketing authorization in days by country

---


\(^2\) The basket of products that is included in the three reimbursement measures gets smaller and therefore time to reimbursement is calculated over a different basket of drugs in each case.
3.3 OVERALL RESULTS

SUMMARY

The relative international performance of Canada’s public drug plans is illustrated in Figure 7. Countries that fall into the upper left hand quadrant showed higher rates of public reimbursements for new medicines and shorter time to public reimbursement. Countries in the bottom right quadrant showed lower rates of reimbursement, and longer time to reimbursement. Relative to the average bubble size, countries with a smaller/larger bubble size had more/less restricted reimbursement than the average across countries.

Figure 7: Overall comparison of countries based on three metrics: percentage reimbursed of new medicines approved, quality of reimbursement, and time to reimbursement from marketing authorization.
This report represents a comprehensive assessment of access to new medicines within the public drug plans of 20 comparable OECD countries. The proportion of new medicines that are publicly reimbursed as well as the quality of reimbursement and time to reimbursement was assessed and compared with a focus on how Canada compares to its global peers.

Using a population coverage definition comparable with global counterparts (reimbursement for $\geq 80\%$ of the eligible national public drug plan population), Canada ranked 18th out of 20, with only 37% of new medicines being reimbursed across the country. Canada also ranked low for the length of time before reimbursement was granted in public drug plans, taking on average 449 days from new drug approval to reimbursement. In addition, a large proportion (90%) of the new medicines reimbursed in Canada came with restrictions limiting patient access in publicly funded drug plans.

It is important to get an evidence-based understanding of how we compare to global counterparts in providing access to new medicines. The findings of this report provide a comparative framework which can be used on an annual basis for informing future policy decision-making. It may also serve as a starting point to look deeper into countries that are highly successful at providing timely access to new medicines for their populations to understand how this can be achieved, and what lessons could be applied to the Canadian context.
5.1 REPORT LIMITATIONS

This report compared public reimbursement across 20 OECD countries to highlight differences in access to medicines. It should be noted that while this comparison gives an understanding of public access to medicines, overall access may be represented more fully by considering both public and private reimbursement systems, depending on the health care system structure.

Comparisons were made given a specific time period and only new medicines that were granted market authorization between 2010 and 2014 were considered. The date that market authorization was granted depends greatly on both the manufacturer’s decision and timing to submit their application, as well as the length of time that is required for a country to make their decision. As such, the mix of products analyzed varied by country. This report does not make conclusions on the time the same group of products took to achieve public reimbursement, rather the real-world access experienced in each country.

The determination of launch and reimbursement status was made using data current to December 2015, providing a snapshot in time. Updating the results in the future may provide insight into how access is evolving in different countries.

A new medicine’s first reimbursement category and date within a country is the only category/date considered. Comparative examination of delistings or changes in medicine reimbursement over time across all countries is not systematically possible however not anticipated to impact the overall country access profile.
Finally, due to the uniqueness of each country’s scheme, the methodologies and sources for determining reimbursement status, level, and date were not identical across all countries. The methodology used was developed to provide a balanced and fair view across all countries, however, the results should be interpreted with an understanding of the particular environment in each country.

### 5.2 METHODOLOGICAL CONSIDERATIONS

The average value calculated in all analyses exclude values for CA₁ (listed in at least one provincial drug plan), CA₂ (covered for at least 50% of the eligible national public drug plan population), US₁ (covered in at least one of the six plans considered) and US₂ (covered for 50% of the population covered under any of the four plans considered).

#### 5.2.1 PRODUCT EXCLUSIONS

New medicines were defined as being new molecular entities or combinations of existing molecules containing at least one new molecular entity. Products where the molecule had been launched previously in another indication prior to 2010 were excluded from the analysis. When the same molecule was launched as two separate products, only the first product was included in the analysis as the following product was no longer within the definition of a new molecular entity. When two products of the same molecule but different indications or within combination with existing molecules were granted market authorization on the same day, the molecule with first launch and then, if necessary to delineate, first reimbursement in hierarchical order were included in the analysis.

#### 5.2.2 REIMBURSEMENT DATA COVERAGE

Reimbursement status, level, and dates were not available through IMS Health data for Australia, New Zealand, South Korea and US. As such, this information was determined from publicly available health agency sources.

Products where the reimbursement decision was still pending were considered to be not reimbursed.

The methodology used was developed to provide a balanced and fair view across all countries, however, the results should be interpreted with an understanding of the particular environment in each country.

### CANADA

Listing information, including listing date and listing status on provincial formularies was extracted from the IMS Brogan, iMAM database. Since cancer products in some provinces are reimbursed outside of the provincial drug formulary (e.g. Cancer agencies), the listing information for cancer medicines was obtained from both the Canadian Agency for Medicines and Technologies in Health (CADTH) and the pan Canadian Oncology Drug Review (pCODR). Product reimbursement status was assessed for each of the 10 provinces, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Newfoundland and Labrador, and Prince Edward Island. Reimbursement data for federal and territorial government drug programs were not considered in the analysis. Additionally, reimbursement data for oncology intravenous (IV) products in Quebec was not available and therefore these products were excluded from the analysis for Quebec.
UNITED KINGDOM

Reimbursement levels were taken from NICE guidance, assuming that the 211 clinical commissioning groups (CCG) who comprise the payers, typically follow NICE guidelines. Medicines covered under the national Cancer Drugs Fund were also considered to be reimbursed with restrictions, given the prior authorization required for patients to access the program. Decisions for Scotland from SMC were not included in this study. Reimbursement date was determined using IMS Health data, and indicated the date on which the product became available for coverage, rather than the date on which NICE issued guidance or the Cancer Drugs Fund made a coverage decision. Although not feasible for all countries, in light of the Cancer Drugs Fund impactful announcement of delisting of a number of previously covered cancer medicines, the delisting of these medicines was examined and included if relevant for the UK list of reimbursed new medicines.

UNITED STATES

Public reimbursement was determined based on Medicare Part B and Part D plan coverage. Part B medicines were considered reimbursed for all levels of coverage (covered in one plan, covered for 50% of the eligible national public drug plan population, and covered for 80% of the eligible national public drug plan population) if they had a maximum reimbursement price listed by the Centre for Medicare and Medicaid Services.

Part D coverage was determined across the six largest managed Medicare plans that combined cover 83% of Medicare lives: Aetna, Cigna Corporation, Express Script, Humana, SilverScript, and United Health Care. The level of reimbursement was weighted according to the population covered by each plan. Listing information by insurer is published annually, with the latest list available from January 2016 being used in this analysis.

Medicaid, a public insurance provider in the US is implemented and managed at the State level, typically covers all FDA-approved out-patient medicines to label, and manages access through preferred drug lists. Some product types are excluded from reimbursement by federal government allowance. Reimbursement under Medicaid also requires that the manufacturer agrees to enroll in the defined federal schemes. Due to the manufacturer involvement and management systems, reimbursement under Medicaid has not been included in this analysis.
TOTAL NEW MEDICINES LAUNCHED AND REIMBURSED BY COUNTRY

Since each country had a different basket of medicines based on health regulatory approvals, the number of medicines differed by country. The number of new medicines launched and granted reimbursement is shown in Table 2, below.

Table 2: Number of products launched and reimbursed by country

<table>
<thead>
<tr>
<th>Country</th>
<th># Medicines launched</th>
<th># Medicines reimbursed</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>108</td>
<td>108</td>
</tr>
<tr>
<td>AU</td>
<td>90</td>
<td>66</td>
</tr>
<tr>
<td>BE</td>
<td>88</td>
<td>85</td>
</tr>
<tr>
<td>CA₁</td>
<td>108</td>
<td>86</td>
</tr>
<tr>
<td>CA₂</td>
<td>108</td>
<td>71</td>
</tr>
<tr>
<td>CA₃</td>
<td>108</td>
<td>45</td>
</tr>
<tr>
<td>CH</td>
<td>106</td>
<td>98</td>
</tr>
<tr>
<td>DE</td>
<td>115</td>
<td>114</td>
</tr>
<tr>
<td>ES</td>
<td>89</td>
<td>88</td>
</tr>
<tr>
<td>FI</td>
<td>95</td>
<td>81</td>
</tr>
<tr>
<td>FR</td>
<td>75</td>
<td>74</td>
</tr>
<tr>
<td>IE</td>
<td>93</td>
<td>91</td>
</tr>
<tr>
<td>IT</td>
<td>95</td>
<td>90</td>
</tr>
<tr>
<td>JP</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>KO</td>
<td>84</td>
<td>59</td>
</tr>
<tr>
<td>NL</td>
<td>99</td>
<td>86</td>
</tr>
<tr>
<td>NO</td>
<td>99</td>
<td>77</td>
</tr>
<tr>
<td>NZ</td>
<td>31</td>
<td>12</td>
</tr>
<tr>
<td>PO</td>
<td>78</td>
<td>43</td>
</tr>
<tr>
<td>SE</td>
<td>102</td>
<td>86</td>
</tr>
<tr>
<td>UK</td>
<td>111</td>
<td>105</td>
</tr>
<tr>
<td>US₁</td>
<td>143</td>
<td>125</td>
</tr>
<tr>
<td>US₂</td>
<td>143</td>
<td>96</td>
</tr>
<tr>
<td>US₃</td>
<td>143</td>
<td>76</td>
</tr>
</tbody>
</table>

5.2.3 HOSPITAL VS. RETAIL REIMBURSEMENT

For some products, the reimbursement status depended on the setting where the drug was administered: hospital vs. retail. In many countries, medicines administered in the hospital are automatically reimbursed, (inclusion for in-patient vs. out-patient varies by country). Some products that are primarily administered in a retail setting may sometimes be given in the hospital setting where they would be reimbursed, thus potentially distorting the overall reimbursement assessment for a mainly retail product. For the purposes of this analysis, products that were not reimbursed in a retail setting, but reimbursed in a hospital setting were counted only if they were primarily a hospital-based product.

5.2.4 REIMBURSEMENT QUALITY

CANADA

The number of products with full benefit was calculated as a weighted average by eligible national public drug plan population across the included provinces. The number of products with restricted benefit was calculated by subtracting the weighted average number of products with full benefit from the total number of reimbursed products. Reimbursement level was calculated for each of the three coverage benchmarks examined (listed in at least one province, available for 50% of the eligible national public drug plan population, and available for 80% of the eligible national public drug plan population).
UNITED STATES

Products requiring prior authorizations, step edits, or quantity limits were considered to be restricted. If none of these applied, then the product was considered to be fully reimbursed.

UNITED KINGDOM

Reimbursement quality was determined from guidance issued by NICE. Products were considered to have restricted reimbursement when the NICE guidance gave a positive recommendation with patient access restrictions beyond the product label. Products where no NICE guidance was issued, or where NICE gave a positive recommendation with no further restrictions beyond the label were considered “fully reimbursed”.

5.2.5 LAUNCH AND REIMBURSEMENT DATES

Launch and reimbursement dates were determined from IMS Health Pricing Insights™ database as outlined in section 1.7 with the following exclusions:

- The launch date in all countries was defined as the date of introduction of a new product to the market captured in the IMS Health production system; launch date could be defined as either the date from which sales start to accrue or the date of launch by the manufacturer. Launch date for the Netherlands was defined as the date when the pharmacy organization officially issued the relevant code for a new product. Due to the disparity between these definitions, launch date for the Netherlands was excluded from the analysis.

- Some products for which the reimbursement date wasn’t available were also excluded from the analysis.

Time to launch was inclusive of the time taken for the manufacturer to decide to launch their product.
5.3 DATA SOURCES

5.3.1 MARKETING AUTHORIZATION


5.3.2 LAUNCH STATUS AND LAUNCH DATE

All countries: IMS Health MIDAS Quantum™ is a unique global market measurement platform used by pharmaceutical professionals to assess international markets, product portfolio performance, understand disease treatment & benchmark promotional mix & expenditure

DETAILS

• Over 94% of the global prescription universe; retail and hospital channels
• Incorporates sales, promotional and medical data
• Accurately details estimated product volumes, trends and market share by product and therapy class
• Multiple market country comparisons
• Customized presentation
• Breadth & depth of information:
  500,000 products, 5,000,000 packs, 18,000 manufacturers, and 8,000 ingredients
• Historical data: 12 years sales (retail/hospital) volume and prices, and kilogram sales, 6 years primary care prescribing and promotional activity
5.3.3 REIMBURSEMENT STATUS, LEVEL, AND DATE

Canada: IMS Brogan iMAM database: iMAM® is a comprehensive online resource for market access information needs. It displays up-to-date information on the current and historical formulary listing status of drug products across Canada; IMS Brogan PharmaStat® database: PharmaStat® provides convenient insight into the actual payment activities of public and private plans. It provides an accurate picture of drug plan utilization to help with market sizing, formulary reimbursement tracking, market share estimation and performance benchmarking, allowing the user to detect and monitor trends as they occur.

Canadian Agency for Medicines and Technologies in Health (CADTH), pan Canadian Oncology Drug Review (pCODR), http://www.cadth.ca/

EU countries and Japan: IMS Pricing Insights database™. A database service from IMS Health focused on global pharmaceutical regulated list prices & reimbursement information, combined with analytical reporting and international standardization for ease of use in pharmaceutical price management. Supplemental reimbursement level information was obtained for France, Germany, Italy, Norway, Sweden and the United Kingdom as detailed below.


Germany: Gemeinsamer Bundesausschuss, http://www.english.g-ba.de/benefitassessment/resolutions/

Italy: Agenzia Italiano del farmaco, http://www.agenziafarmaco.gov.it/it/content/note-aifa

Sweden: The Dental and Pharmaceutical Benefits Agency (TLV), http://www.tlv.se/


**United Kingdom:** The National Institute for Health and Care Excellence, [https://www.nice.org.uk/guidance](https://www.nice.org.uk/guidance)

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

**VISION STATEMENT**

Canadians living healthier and longer lives through access to innovative medicines and vaccines.

**MISSION STATEMENT**

As the national voice of research-based pharmaceutical companies, Innovative Medicines Canada advocates for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.